Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 28c

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $1.11, $0.28 better than the analyst estimate of $0.83. Revenue for the quarter came in at $60.7 million versus the consensus estimate of $64.26 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
• FirstCash to acquire UK pawn operator Ramsdens for £206 million